Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Appunti di Terapia

PDF MeBrain

Malattia di Kawasaki: quale dose di immunoglobuline nei bambini grandi?

Kawasaki disease: what dose of immunoglobulins should be used in old children?

Lorenzo Mambelli1, Alessandra Iacono1, Giovanna Rametta2, Federico Marchetti1
1UOC di Pediatria e Neonatologia, 2Servizio di Farmacia Ospedaliera
Ospedale di Ravenna, AUSL della Romagna

Novembre 2020 | DOI: 10.53126/MEBXXIII231

Abstract
In a retrospective study conducted on a population of Japanese children with a weight ≥ 25 kg and with Kawasaki disease, no significant difference has been observed for the onset of coronary aneurysms, intravenous immunoglobulin (IVIg) resistance, duration of the hospitalisation and adverse treatment effects among the groups treated with 2 g/kg and 1 g/kg doses of IVIg. New randomised controlled studies are desirable to check the most appropriate IVIg dose for old children, also considering the cortisone treatment in association with the IVIg treatment firstly.
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Suzuki T, Nobuaki Michihata N, Yoshikawa T, et al. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more. Eur J Pediatr 2020 [Online ahead of print, Aug 29].
  2. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135(17):e927-9.
  3. Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital J Pediatr 2018;44(1):102.
  4. Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. Ital J Pediatr 2018;44(1):103.
  5. Cimaz R, Fanti E, Mauro A, Voller F, Rusconi F. Epidemiology of Kawasaki disease in Italy: surveillance from national hospitalization records. Eur J Pediatr 2017;176:1061-5.
  6. Yanagimoto K, Nomura Y, Masuda K. Investigation of Kawasaki disease patients with body weights above twenty-five kilograms. Ped Cardiol Card Surg 2012;28:174-8.
  7. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349(12):1157-67.
  8. Pansa P, Giancane G, Duse M. I meccanismi molecolari delle immunoglobuline per via endovenosa. Rivista di Immunologia e Allergologia Pediatrica 2012;1:11-7.
  9. Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol 2015;11(7):819-25.
  10. Marchetti F. La fine della questione sull’uso del cortisone nella malattia di Kawasaki? Medico e Bambino pagine elettroniche 2014;17(3).
  11. Ae R, Abrams JY, Maddox RA, et al. Corticosteroids added to initial intravenous immunoglobulin treatment for the prevention of coronary artery abnormalities in high-risk patients with Kawasaki disease. J Am Heart Assoc 2020;9:e015308.
  12. Friedman KG, Gauvreau K, Baker A, et al. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Arch Dis Child 2020 ([Published Online First, Sep 17].
  13. Sevenoaks L, Tulloh R. Should we use steroids as primary therapy for Kawasaki disease? Arch Dis Child 2020;105:1120-4.
  14. Dionne A, Burgner D, De Ferranti S, Singh-Grewal D, Newburger J, Dahdah N. Variation in the management of Kawasaki disease. Arch Dis Child 2020;105(10):1004-6.
  15. Nishikawa M, Ichiyama T, Hasegawa M, Kawasaki K, Matsubara T, Furukawa S. Safety from thromboembolism using intravenous immunoglobulin therapy in Kawasaki disease: study of whole-blood viscosity. Pediatr Int 2003;45(2):156-8.
  16. Baba R. Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease. Recent Pat Cardiovasc Drug Discov 2008;3(2):141-4.
  17. Ventura G, Rabusin M, Spinelli E, Badolato R. Utilizzo delle immunoglobuline endovenose nella pratica clinica in Pediatria. Medico e Bambino 2009;28(6):371-81.
  18. AIFA. Ig VENA 50 g/l, soluzione per infusione. Immunoglobulina umana normale (IVIg) per uso endovenoso. Informazioni per l’utilizzatore. Documento reso disponibile da AIFA il 28/04/2020.